author-photo

Isabelle Fleury

Hôpital Maisonneuve-Rosemont

10

Papers

15

Citations

Citation Trend

Filter By

Papers (7) Sort By

Journal Conference Others

Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Sarcopenia and clinical evaluation in predicting treatment tolerability and outcomes in aggressive non-Hodgkin B cell lymphoma.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
CORRELATIVE ANALYSES OF CYTOKINE RELEASE SYNDROME AND NEUROLOGICAL EVENTS IN TISAGENLECLEUCEL-TREATED RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA PATIENTS

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (4)
Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients

2019 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (3)
CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH RELAPSED FOLLICULAR LYMPHOMA FOLLOWING RETREATMENT WITH SECOND-LINE RITUXIMAB-CONTAINING CHEMOTHERAPY

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (0)
INTRAVENOUS IMMUNOGLOBULIN THERAPY USE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA TREATED WITH TISAGENLECLEUCEL IN THE JULIET TRIAL

2019 Hematological Oncology
Show All
- Source
- Cite
- Save
Citations (2)
Rituximab Maintenance for Two Years in Previously Untreated Follicular Lymphoma: No Difference in Outcome between Patients Receiving Treatment at Two Month Versus Three Month Interval

2017 Blood
Show All
- Source
- Cite
- Save
Citations (1)